Novartis's $30 Billion Deal Spree Triggers a Boardroom Reckoning
Novartis NYSE:NVS, the global innovative-medicines company, confronted sharper questions over its dealmaking strategy Friday after clinical setbacks weakened confidence in recent acquisitions. Its U.S.-listed shares traded at $137.58, yet remained roughly 14% lower across five sessions. The picture…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.